Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubidecarenone - Berg Pharma

Next Previous
X
Search
Drug Profile

Ubidecarenone - Berg Pharma

Alternative Names: API-31510; BP 31510; BPM-31510; BPM31510IV; BPM31510T; C-31510; c31510; Coenzyme Q10 - Cytotech; Coenzyme Q10 injectable nanosuspension; CoQ10 - Cytotech; Ubiquinone injectable nanosuspension

Latest Information Update: 11 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytotech Labs
  • Developer Berg Pharma; National Cancer Institute (USA); Stanford Cancer Institute; Stanford University; University of Miami
  • Class Antihyperlipidaemics; Antineoplastics; Benzoquinones; Cardiotonics; Cardiovascular therapies; Coenzymes; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Electron transport chain complex protein modulators; Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Epidermolysis bullosa; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ataxia; Glioblastoma; Pancreatic cancer; Squamous cell cancer
  • Phase I/II Glioma
  • Phase I Epidermolysis bullosa; Sarcopenia
  • Discontinued Basal cell cancer; Leukaemia; Lung cancer; Solid tumours; Wounds

Most Recent Events

  • 07 Nov 2024 Pharmacodynamics data from a preclinical trial in Cancer released by BPGbio
  • 01 Nov 2024 US FDA granted Rare Pediatric Disease designation (RPDD) for Ubidecarenone in Epidermolysis bullosa
  • 01 Nov 2024 BPGbio plans a phase II/III trial for Epidermolysis bullosa in 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top